CELLTRION Healthcare Australia and Australian-owned Arrotex Pharmaceuticals have entered into a strategic agreement to launch two new biosimilar medicines – Steqeyma (ustekinumab) and Omlyclo (omalizumab).

Both are listed on the Pharmaceutical Benefits Scheme (PBS) and available in pharmacies from today, and are the first PBS-listed biosimilars in their respective categories.

Steqeyma is indicated for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis, while Omlyclo is listed for uncontrolled severe asthma/ allergic asthma, and severe chronic spontaneous urticaria.

As the sponsor of the medicines, Celltrion will be responsible for engaging with key prescribing physicians, while Arrotex will be the brand’s exclusive distribution partner in Australia, covering community pharmacy distribution as well as representation across the dermatology segment.

Arrotex Chief Commercial Officer Hayley Tamborini (pictured) said: “Our new alliance with Celltrion is complementary and important for many reasons.”

“We are proud that Arrotex’s strong market presence in community pharmacy and extensive distribution networks can truly be a game-changer in delivering Celltrion’s biosimilars to the patients who need them most,” she continued.

“Arrotex continues to focus on exclusive and first-to-market launches to bring increased value to community pharmacy,” Tamborini concluded.

The post Arrotex and Celltrion partner on biosimilars appeared first on Pharmacy Daily.